<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182830</url>
  </required_header>
  <id_info>
    <org_study_id>1245.29</org_study_id>
    <nct_id>NCT02182830</nct_id>
  </id_info>
  <brief_title>24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Empagliflozin (10mg, 25mg) Administered Orally, Once Daily Over 24 Weeks in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This trial is designed to investigate the efficacy and safety of empagliflozin compared with
      placebo in hypertensive black/African Americans with type 2 Diabetes Mellitus. Since
      hyperglycaemia and hypertension are key risk factors for both micro- and macrovascular
      complications, assessment of both glucose and BP lowering effects of empagliflozin in
      hypertensive African American patients with type 2 Diabetes Mellitus could provide clinically
      highly relevant, new information for the use of empagliflozin.

      Essential hypertension is four times more common in African Americans than in Caucasians.

      One of the risk factors for hypertension is sodium sensitivity and approximately one third of
      the essential hypertensive population is responsive to sodium intake. There is a higher
      association of hypertension with sodium sensitivity in African American patients with type 2
      Diabetes Mellitus.

      The treatment duration of this trial (24 weeks) will enable assessment of the clinically
      relevant endpoint of a decrease in HbA1c, a well accepted measurement of chronic glycaemic
      control and the key secondary endpoints of decreases in systolic BP (SBP) and diastolic BP
      (DBP) at 12 and 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 25, 2014</start_date>
  <completion_date type="Actual">May 18, 2017</completion_date>
  <primary_completion_date type="Actual">May 18, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change from baseline in HbA1c (%) at 24 weeks is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. Restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) model is used in the statistical analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Change from baseline in mean 24-hour ambulatory Systolic blood pressure SBP at Week 12 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Trough Mean Ambulatory SBP at Week 12</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Changes from baseline in trough mean ambulatory SBP at Week 12 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight at Week 24</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Changes from baseline in body weight at Week 24 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated SBP at Week 12</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Change from baseline in trough seated SBP (mmHg) at Week 12 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change from baseline in mean 24-hour ambulatory SBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 12. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated SBP (mmHg) at Week 24</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change from baseline in trough seated SBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated DBP (mmHg) at Week 12</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Change from baseline in trough seated DBP (mmHg) at Week 12 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Seated DBP (mmHg) at Week 24</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change from baseline in trough seated DBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>starting dose 10mg; forced titration after 4 weeks 25mg dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>starting dose 10mg; forced titration after 4 weeks 25mg dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin low dose</intervention_name>
    <description>starting dose 10mg; forced titration after 4 weeks 25mg dose</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>starting dose 10mg; forced titration after 4 weeks 25mg dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin high dose</intervention_name>
    <description>starting dose 10mg; forced titration after 4 weeks 25mg dose</description>
    <arm_group_label>Empagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of Type 2 Diabetes Mellitus (T2DM) prior to informed consent.

          -  Male and female black/African American patients on diet and exercise regimen who are
             EITHER drug-naïve (defined as absence of any oral antidiabetic therapy, glucagon like
             peptide-1 (GLP-1) analog or insulin for 12 weeks, 16 weeks for pioglitazone prior to
             randomisation) OR pre-treated with stable dose of

               -  Metformin only, or

               -  Sulfonylurea only, or

               -  Dipeptidyl peptidase-4 (DPP-4) inhibitor only, or

               -  metformin plus sulfonylurea, or

               -  metformin plus DPP-4 inhibitor. Treatment has to be unchanged for a minimum of 12
                  weeks prior to randomization. Dose for metformin: maximum tolerated dose The
                  maximum daily dose of Sulfonylurea (SU) or DPP-4 inhibitor should not exceed that
                  stated in the local label.

          -  HbA1c of &gt;= 7.0% (53 mmol/mol) and ≤ 11.0% (97 mmol/mol) at Visit 1 (screening).

          -  Mean seated Systolic Blood Pressure (SBP) 140-180 mmHg at Visit 1 (screening).

          -  Successful completion of baseline Ambulatory Blood Pressure Monitor (ABPM) testing
             with a mean SBP 135-175 mmHg prior to randomisation.

          -  Treatment with stable doses of at least one but not more than 4 antihypertensive
             medication &gt;= 4 weeks prior to randomisation.

          -  Age &gt;= 18 years at Visit 1 (screening)

          -  Signed and dated written informed consent by date of Visit 1 in accordance with Good
             Clinical Practice (GCP) and local legislation

        Exclusion criteria:

          -  Uncontrolled hyperglycemia with a glucose level &gt;270 mg/dl (&gt;15.0 mmol/L) after an
             overnight fast during placebo run-in (includes Visit 2.1) and confirmed by a second
             measurement (not on the same day).

          -  Exposure to any other antidiabetic medication within 12 weeks prior to randomisation
             other than metformin, sulfonylurea, Dipeptidyl peptidase-4 (DPP-4) inhibitor,
             metformin plus sulfonylurea or metformin plus DPP-4 inhibitor.

          -  Current hypertension treatment with oral Minoxidil (topical minoxidil for hair growth
             is allowed).

          -  Mean seated Systolic Blood Pressure (SBP) ≥181 mmHg during placebo run-in visit and
             confirmed by a second measurement (not on the same day) preferably within one day.

          -  Upper arm circumference that exceeds the upper circumference level of the cuff size of
             either Ambulatory Blood Pressure Monitor (ABPM) and/or (BP) measurement device used in
             the study.

          -  Night shift workers who routinely sleep during the daytime and/or whose work hours
             include midnight.

          -  Diagnosis of autoimmune diabetes/Type I diabetes mellitus, monogenic (neonatal or
             maturity onset diabetes of the young (MODY)) diabetes or Type I diabetes in
             adults/latent autoimmune diabetes of adults (LADA) per investigator or patient medical
             history at the time of Visit 1 (screening).

          -  Known or suspected secondary hypertension (e.g. renal artery
             stenosis,phaeochromocytoma, Cushing's disease).

          -  History or evidence of hypertensive retinopathy (Keith-Wagener grade III or IV) and/or
             hypertensive encephalopathy.

          -  Clinically significant valvular heart disease or severe aortic stenosis in the opinion
             of the investigator.

          -  Acute coronary syndrome (non- ST wave elevated myocardial infarction (STEMI), STEMI
             and unstable angina pectoris), stroke or transient ischemic attack within 3 months
             prior to informed consent.

          -  Indication of liver disease, defined by serum levels of either Alanine
             Aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase(SGPT)), Aspartate
             Aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)), or alkaline
             phosphatase above 3 x upper limit of normal (ULN) as determined during screening
             and/or run-in phase.

          -  Impaired renal function, defined as Estimated Glomerular Filtration Rate (eGFR)&lt; 45
             ml/min/1.73m2 (moderate renal impairment, chronic kidney disease epidemiology
             collaboration Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula) as
             determined during screening and/or run-in phase.

          -  Bariatric surgery within the past two years and other gastrointestinal surgeries that
             induce chronic malabsorption.

          -  Medical history of cancer (except for basal cell carcinoma) and/or treatment for
             cancer within the last 5 years.

          -  Blood dyscrasias or any disorders causing hemolysis or unstable Red Blood Cells (e.g.
             malaria, babesiosis, haemolytic anaemia, thalassemia, sickle cell anaemia (sickle cell
             trait is allowed)).

          -  Medical history and signs and symptoms of diabetic autonomic neuropathy.

          -  Treatment with anti-obesity drugs 3 months prior to randomisation (i.e. surgery,
             aggressive diet regimen, etc.) leading to unstable body weight.

          -  Current treatment with systemic steroids at time of informed consent or change in
             dosage of thyroid hormones within 6 weeks prior to informed consent or any other
             uncontrolled endocrine disorder except Type 2 Diabetes Mellitus (T2DM) in the opinion
             of the investigator.

          -  Pre-menopausal women (last menstruation &lt;=1 year prior to informed consent) who:

               -  are nursing or pregnant or

               -  are of child-bearing potential and are not practicing an acceptable method of
                  birth control, or do not plan to continue using this method throughout the study
                  and do not agree to submit to periodic pregnancy testing during participation in
                  the trial. Acceptable methods of birth control include tubal ligation,
                  transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable
                  or injectable contraceptives, complete sexual abstinence (if acceptable by local
                  authorities), double barrier method and vasectomised partner.

          -  Alcohol, drug or confectionary liquorice abuse within the 3 months prior to informed
             consent that would interfere with trial participation or any ongoing condition leading
             to a decreased compliance to study procedures or study drug intake in the
             investigator's opinion.

          -  Intake of an investigational drug in another trial within 30 days prior to intake of
             study medication in this trial; or participating in another trial (involving an
             investigational drug and/or follow-up) after discontinuing medication in that trial.

          -  Any other clinical condition that would jeopardize patient's safety while
             participating in this clinical trial in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longwood Research</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Center, LLC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mobile Medical and Diagnostic Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology and Medicine Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larry Watkins, M .D.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute Inc.</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Center for Clinical Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Alexander Ford, M.D.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Associates Medical Group</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Research Group, Inc.</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Clinical Research Inc.</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Partners Clinical Research LLC</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Research Center</name>
      <address>
        <city>Opa-locka</city>
        <state>Florida</state>
        <zip>33054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Internist</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accord Clinical Research, LLC</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alternative Solutions Medical Research and Prevention Center</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research - US, LLC</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morehouse School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Clinical Research Centers</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert F. Johary MD, PC</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sestron Clinical Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR-Mount Vernon Clinical Research, LLC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eagle's Landing Diabetes and Endocrinology</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H. Stroger Jr. Hospital of Cook Country</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigators Research Group, LLC</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Regional Research and Education Services, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Institute of Research Studies</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phillips Medical Services, PLLC</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Research</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090-4700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research Inc</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accent Clinical Trials</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Offic of Dr. Eric Cheng</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203-1203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthwise Medical Associates</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modern Medical</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erie County Medical Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott Research, Inc.</name>
      <address>
        <city>Laurelton</city>
        <state>New York</state>
        <zip>11413</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medex Healthcare Research, Inc.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurelton Heart Specialist, PC</name>
      <address>
        <city>Rosedale</city>
        <state>New York</state>
        <zip>11422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Internal Medicine, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PhysiqueMed Clinical Trials</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triad Clinical Trials</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Health Care, P.A.</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hometown Urgent Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Clinical Research</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Today Clinical Research, Oklahoma City</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suburban Research Associates</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research South</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TLM Medical Services, LLC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amistad Clinical Research Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Pharmaceutical Rsch</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berkley Family Practice</name>
      <address>
        <city>Moncks Corner</city>
        <state>South Carolina</state>
        <zip>29461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Cardiology Clinical Research Institute, LLC</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Partners, Inc</name>
      <address>
        <city>Varnville</city>
        <state>South Carolina</state>
        <zip>29944</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memphis Veterans Affairs Medical Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Green Clinic PC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwind Medical Specialists</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Clinic of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cullen Family Practice, PLLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kelsey-Seybold Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Family Health Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millennium Clinical Trials LLC</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Clinical Research, LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dominion Medical Associates, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners, LLC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medical Clinic</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <results_first_submitted>May 16, 2018</results_first_submitted>
  <results_first_submitted_qc>July 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2018</results_first_posted>
  <last_update_submitted>July 4, 2018</last_update_submitted>
  <last_update_submitted_qc>July 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02182830/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02182830/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In this Phase 3b, multi-centre trial, a total of 719 patients were screened by 92 centres across the United States. The first centre was initiated on 25 Jul 2014. Of the 719 screened patients, 297 patients entered the placebo run-in phase of the trial and 166 were subsequently randomised to double-blind treatment</recruitment_details>
      <pre_assignment_details>Empagliflozin was administered at a starting dose of 10 milligram (mg) once daily. At Week 4, patients were dose escalated to a dose of 25 mg once daily. These doses were selected based on the results from previous dose-finding studies</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 10 Mg-25mg</title>
          <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomised Set (RS)</title>
              <participants_list>
                <participants group_id="P1" count="79">From started, 2 duplicate patients and 2 patients from one site were removed</participants>
                <participants group_id="P2" count="82">From started, 1 patient from one site was removed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Set (TS)</title>
              <participants_list>
                <participants group_id="P1" count="77">From RS, 1 duplicate patient and 1 non treated patient was removed</participants>
                <participants group_id="P2" count="80">From RS, 1 duplicate patient and 1 non treated patient was removed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial stopped, reason missing</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS): All patients randomised, treated with at least one dose of trial drug, and with a baseline and at least one on-treatment glycated haemoglobin (HbA1c)value. The FAS was the basis for the primary efficacy analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin 10 Mg-25mg</title>
          <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Full analysis set (FAS): All patients randomised, treated with at least one dose of trial drug, and with a baseline and at least one on-treatment HbA1c value. The FAS was the basis for the primary efficacy analysis.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="9.3"/>
                    <measurement group_id="B2" value="56.5" spread="9.3"/>
                    <measurement group_id="B3" value="56.8" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline hemoglobin A1c (HbA1c) [%]</title>
          <description>Mean and standard deviation for Baseline HbA1c [%] is presented</description>
          <population>FAS</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.51" spread="1.12"/>
                    <measurement group_id="B2" value="8.66" spread="0.92"/>
                    <measurement group_id="B3" value="8.59" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline estimated glomerular filtration rate (eGFR)</title>
          <population>FAS</population>
          <units>mL/min/1.73m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.49" spread="20.79"/>
                    <measurement group_id="B2" value="91.15" spread="18.95"/>
                    <measurement group_id="B3" value="91.31" spread="19.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks</title>
        <description>Change from baseline in HbA1c (%) at 24 weeks is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. Restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) model is used in the statistical analysis.</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>Full analysis set (FAS) observed cases (OC); FAS: All patients randomised, treated with at least one dose of trial drug, and with a baseline and at least one on-treatment HbA1c value.
Observed cases will set all values measured after antidiabetic rescue medication to missing</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks</title>
          <description>Change from baseline in HbA1c (%) at 24 weeks is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. Restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) model is used in the statistical analysis.</description>
          <population>Full analysis set (FAS) observed cases (OC); FAS: All patients randomised, treated with at least one dose of trial drug, and with a baseline and at least one on-treatment HbA1c value.
Observed cases will set all values measured after antidiabetic rescue medication to missing</population>
          <units>percentage of glycated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.14"/>
                    <measurement group_id="O2" value="-0.71" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM model : “HbA1c baseline,” “treatment,” “renal function,” “pre-treatment with metformin,” “visit,” “visit by treatment interaction,” and “HbA1c baseline by treatment interaction.” “Treatment,” “renal function,” “pre-treatment with metformin,” “visit,” and “visit by treatment interaction” were fixed classification effects, and “HbA1c baseline” was a linear covariate. The interaction “visit by HbA1c baseline interaction” was based on the linear covariate “HbA1c baseline.”</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A hierarchical multiple testing procedure was used to evaluate superiority of the primary endpoint</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12</title>
        <description>Change from baseline in mean 24-hour ambulatory Systolic blood pressure SBP at Week 12 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>FAS LOCF-H; LOCF-H= Last observation carried forward without values following antidiabetic rescue medication and/or a change in antihypertensive therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (SBP) at Week 12</title>
          <description>Change from baseline in mean 24-hour ambulatory Systolic blood pressure SBP at Week 12 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
          <population>FAS LOCF-H; LOCF-H= Last observation carried forward without values following antidiabetic rescue medication and/or a change in antihypertensive therapy</population>
          <units>millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.90" spread="1.47"/>
                    <measurement group_id="O2" value="-6.10" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>change from baseline in mean 24-hour ambulatory SBP at 12 weeks of treatment was evaluated by using an Analysis of Covariance (ANCOVA) model.
The respective model included treatment, renal function, pretreatment with metformin, continuous baseline HbA1c, and continuous baseline of the endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A hierarchical multiple testing procedure was used to evaluate superiority of the endpoint</non_inferiority_desc>
            <p_value>0.0117</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-5.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.24</ci_lower_limit>
            <ci_upper_limit>-1.18</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Trough Mean Ambulatory SBP at Week 12</title>
        <description>Changes from baseline in trough mean ambulatory SBP at Week 12 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>FAS LOCF-H</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Trough Mean Ambulatory SBP at Week 12</title>
          <description>Changes from baseline in trough mean ambulatory SBP at Week 12 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
          <population>FAS LOCF-H</population>
          <units>millimeter of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="1.89"/>
                    <measurement group_id="O2" value="-6.99" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA mode:
The respective model included treatment, renal function, pretreatment with metformin, continuous baseline HbA1c, and continuous baseline of the endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A hierarchical multiple testing procedure was used to evaluate superiority of the endpoint</non_inferiority_desc>
            <p_value>0.0237</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-5.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.16</ci_lower_limit>
            <ci_upper_limit>-0.81</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight at Week 24</title>
        <description>Changes from baseline in body weight at Week 24 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>FAS OC</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight at Week 24</title>
          <description>Changes from baseline in body weight at Week 24 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
          <population>FAS OC</population>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="0.42"/>
                    <measurement group_id="O2" value="-2.21" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM models modelling the key secondary endpoint with continuous baseline HbA1c, continuous baseline key secondary endpoint, treatment, renal function, pretreatment with metformin, visit, visit by treatment interaction, visit by continuous baseline HbA1c interaction, visit by continuous baseline key secondary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A hierarchical multiple testing procedure was used to evaluate superiority of the endpoint</non_inferiority_desc>
            <p_value>0.0382</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated SBP at Week 12</title>
        <description>Change from baseline in trough seated SBP (mmHg) at Week 12 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated SBP at Week 12</title>
          <description>Change from baseline in trough seated SBP (mmHg) at Week 12 is presented. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means. This is a key secondary endpoint</description>
          <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.94" spread="1.82"/>
                    <measurement group_id="O2" value="-7.97" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM models modelling the key secondary endpoint with continuous baseline HbA1c, continuous baseline key secondary endpoint, treatment, renal function, pretreatment with metformin, visit, visit by treatment interaction, visit by continuous baseline HbA1c interaction, visit by continuous baseline key secondary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A hierarchical multiple testing procedure was used to evaluate superiority of the endpoint</non_inferiority_desc>
            <p_value>0.1215</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-4.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.16</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24</title>
        <description>Change from baseline in mean 24-hour ambulatory SBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24</title>
          <description>Change from baseline in mean 24-hour ambulatory SBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
          <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.94"/>
                    <measurement group_id="O2" value="-10.33" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM models modelling the secondary endpoint with continuous baseline HbA1c, continuous baseline secondary endpoint, treatment, renal function, pretreatment with metformin, visit, visit by treatment interaction, visit by continuous baseline HbA1c interaction, visit by continuous baseline secondary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-8.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.74</ci_lower_limit>
            <ci_upper_limit>-3.04</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12</title>
        <description>Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 12. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>FAS (LOCF-H)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (DBP) at Week 12</title>
          <description>Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 12. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
          <population>FAS (LOCF-H)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.90"/>
                    <measurement group_id="O2" value="-3.80" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The respective ANCOVA model includes treatment, renal function, pretreatment with metformin, continuous baseline HbA1c, and continuous baseline of the respective secondary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0069</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-3.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.90</ci_lower_limit>
            <ci_upper_limit>-0.96</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24</title>
        <description>Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean 24-hour Ambulatory DBP (mmHg) at Week 24</title>
          <description>Change from baseline in mean 24-hour ambulatory DBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
          <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="1.24"/>
                    <measurement group_id="O2" value="-6.38" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM models modelling the secondary endpoint with continuous baseline HbA1c, continuous baseline secondary endpoint, treatment, renal function, pretreatment with metformin, visit, visit by treatment interaction, visit by continuous baseline HbA1c interaction, visit by continuous baseline secondary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0058</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-4.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.74</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.35</ci_lower_limit>
            <ci_upper_limit>-1.46</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated SBP (mmHg) at Week 24</title>
        <description>Change from baseline in trough seated SBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated SBP (mmHg) at Week 24</title>
          <description>Change from baseline in trough seated SBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
          <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.83" spread="1.82"/>
                    <measurement group_id="O2" value="-10.26" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM models modelling the secondary endpoint with continuous baseline HbA1c, continuous baseline secondary endpoint, treatment, renal function, pretreatment with metformin, visit, visit by treatment interaction, visit by continuous baseline HbA1c interaction, visit by continuous baseline secondary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-7.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.37</ci_lower_limit>
            <ci_upper_limit>-2.48</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated DBP (mmHg) at Week 12</title>
        <description>Change from baseline in trough seated DBP (mmHg) at Week 12 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated DBP (mmHg) at Week 12</title>
          <description>Change from baseline in trough seated DBP (mmHg) at Week 12 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
          <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="1.09"/>
                    <measurement group_id="O2" value="-4.14" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM models modelling the secondary endpoint with continuous baseline HbA1c, continuous baseline secondary endpoint, treatment, renal function, pretreatment with metformin, visit, visit by treatment interaction, visit by continuous baseline HbA1c interaction, visit by continuous baseline secondary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2402</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.93</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Seated DBP (mmHg) at Week 24</title>
        <description>Change from baseline in trough seated DBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 Mg-25mg</title>
            <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Seated DBP (mmHg) at Week 24</title>
          <description>Change from baseline in trough seated DBP (mmHg) at Week 24 is secondary endpoint. The term &quot;baseline&quot; refers to the last observation prior to randomisation of the patient.
Means presented are the adjusted means.</description>
          <population>FAS OC-H =FAS observed cases without values following a change in antihypertensive therapy (OC-H)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="1.09"/>
                    <measurement group_id="O2" value="-5.55" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MMRM models modelling the secondary endpoint with continuous baseline HbA1c, continuous baseline secondary endpoint, treatment, renal function, pretreatment with metformin, visit, visit by treatment interaction, visit by continuous baseline HbA1c interaction, visit by continuous baseline secondary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0053</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-4.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.49</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.21</ci_lower_limit>
            <ci_upper_limit>-1.29</ci_upper_limit>
            <estimate_desc>Empagliflozin minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events occurring after the first dose of trial medication up to a period of 7 days after the last dose of trial medication (i.e. end of REP); up to 25 weeks</time_frame>
      <desc>All the safety analyses were based on treated set except the serious adverse event analysis. The two patients with multiple participation in the study (counted once as first randomized) and three patients excluded from one site were included back into treated set for the analysis of serious adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients were orally administered Placebo matching empagliflozin 10 mg or 25 mg (1 tablet once daily, morning)</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 10 Mg-25mg</title>
          <description>Patients were orally administered Empagliflozin 10 mg or 25mg (1 tablet once daily, morning over a period of 24 weeks)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

